Alder Biopharmaceuticals, Inc.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 in Phase 3

Quick facts

Phase 3 pipeline

ALD403 · Neurology
ALD403 is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
ALD403 (Eptinezumab) · Neurology
Eptinezumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Alder Biopharmaceuticals, Inc. portfolio CI brief
Alder Biopharmaceuticals, Inc. pipeline updates RSS

Frequently asked questions about Alder Biopharmaceuticals, Inc.

What is Alder Biopharmaceuticals, Inc.'s pipeline?

Alder Biopharmaceuticals, Inc. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include ALD403, ALD403 (Eptinezumab).

Sector hub: All tracked pharma companies